A Safety Study of SGN-CD19A for B-Cell Lymphoma

Not Recruiting

Trial ID: NCT01786135

Age - 12 Years-N/A Condition - Lymphomas: Non-Hodgkin, Diffuse Large B-Cell Lymphoma, Low Grade Lymphoma, Mantle Cell Lymphoma, Pediatric Cancer Gender - All Accepting Healthy Volunteers - No

Purpose

This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)

Official Title

A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Eligibility


Inclusion Criteria:

   - Pathologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma Grade
   3, diffuse large B-cell lymphoma (DLBCL), including transformed follicular histology,
   Burkitt lymphoma, or B-lineage lymphoblastic lymphoma

   - Relapsed, refractory, or progressive disease following at least 1 prior systemic
   therapy. Patients with DLBCL or follicular lymphoma Grade 3 must have also received
   intensive salvage therapy.

   - Eastern Cooperative Oncology Group status of 0 or 1

   - Measurable disease

Exclusion Criteria:

   - Allogeneic stem cell transplant (SCT)

View More
View Less

Intervention(s):

drug: SGN-CD19A

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061

New Trial Alerts

©2024 Stanford Medicine